Cardiff Oncology: Q3 Earnings Snapshot
Cardiff Oncology (CRDF) reported a Q3 loss of $8.9M, or 12 cents per share, beating analyst expectations of a 14 cents per share loss. Revenue was $171,000, exceeding forecasts of $113,000. The company is based in San Diego and operates in the molecular diagnostics sector.
How this was made

The 30-second read
Why it matters
The earnings release provides the first public numbers for the quarter, offering new data for traders.
Market read
Micro‑cap earnings with modest beat on loss but still a loss; likely limited price movement but may attract short‑term traders.
What to watch
The company’s cash position and upcoming clinical milestones are not disclosed but could materially affect future valuation.
Background
Cardiff Oncology is a molecular diagnostic company focused on oncology testing. The Q3 results were generated by Automated Insights from Zacks data.
Ticker impact
Cardiff Oncology reported Q3 loss of $8.9M, 12c EPS loss beating estimates of 14c, revenue $171k beating $113k forecasts.
likely slight downside as market prices in loss despite beat on loss per share.
Micro‑cap earnings with modest beat on loss but still a loss; investors may trim positions.
Market effects
Limited impact on broader biotech sector; reflects ongoing challenges for early‑stage diagnostics firms.
Primarily U.S. micro‑cap investors; no broader regional effect.
Low global relevance.
Counterpoint
Despite the loss, the beat on loss per share could signal improving cost control, suggesting a potential rebound if cash runway extends.
Key entities
- CompanyCardiff Oncology, Inc.
Micro‑cap biotech reporting Q3 earnings.